BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
Nations for Youngsters to Visit- Untamed life Safe-havens All over the Planet Offering Remarkable Creature Experiences
- Most loved Web-based feature: Which Stage Do You Like
- They died 'doing what they loved': The stories of workers in their 80s who died on the job
- Manual for Picking the Ideal Wine Matching
- Manual for Picking the Ideal Wine Matching
- Monetary Strengthening: Assuming Command over Your Cash
- Sustaining Public activity and Connections: Key Methodologies
- Portable Installment Answers for Independent ventures
